Journal of the National Cancer Institute Advance Access originally published online on October 28, 2009
JNCI Journal of the National Cancer Institute 2009 101(22):1593-1594; doi:10.1093/jnci/djp360
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2009.
CORRESPONDENCE |
Response: Re: Antitumor Efficacy Testing in Rodents
Affiliation of author: Biological Testing Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD
Correspondence to: Melinda G. Hollingshead, NCI-Frederick, Division of Cancer Treatment, Fairview Center, Ste 205, 1003 West 7th St, Frederick, MD 21701 (e-mail: hollingm@mail.nih.gov).
| The first 10% of the full text of this article appears below. |
It is clear that pharmacokinetic (PK) and pharmacodynamic (PD) data are important to understanding antitumor activity and in designing experimental protocols for proving or disproving predicted outcomes. However, the approach described by Poggesi et al. requires pharmacokinetic data for every experimental agent being assessed. Although it would be ideal to have such data, conducting pharmacological assay development and validation and assessing the pharmacokinetic parameters in mice